[go: up one dir, main page]

MA34002B1 - Thérapie antivirale - Google Patents

Thérapie antivirale

Info

Publication number
MA34002B1
MA34002B1 MA35145A MA35145A MA34002B1 MA 34002 B1 MA34002 B1 MA 34002B1 MA 35145 A MA35145 A MA 35145A MA 35145 A MA35145 A MA 35145A MA 34002 B1 MA34002 B1 MA 34002B1
Authority
MA
Morocco
Prior art keywords
antiviral therapy
treatment
hiv
aids
combinations
Prior art date
Application number
MA35145A
Other languages
Arabic (ar)
English (en)
Inventor
Mark Richard Underwood
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44319704&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34002(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of MA34002B1 publication Critical patent/MA34002B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne des combinaisons de composés comprenant des inhibiteurs de l'intégrase du vih et d'autres agents thérapeutiques. Lesdites combinaisons peuvent être utilisées dans le cadre de l'inhibition de la réplication du vih, de la prévention et/ou du traitement de l'infection par le vih et du traitement du sida et/ou du syndrome pré-sida.
MA35145A 2010-01-27 2011-01-24 Thérapie antivirale MA34002B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29858910P 2010-01-27 2010-01-27
PCT/US2011/022219 WO2011094150A1 (fr) 2010-01-27 2011-01-24 Thérapie antivirale

Publications (1)

Publication Number Publication Date
MA34002B1 true MA34002B1 (fr) 2013-02-01

Family

ID=44319704

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35145A MA34002B1 (fr) 2010-01-27 2011-01-24 Thérapie antivirale

Country Status (45)

Country Link
US (13) US20120295898A1 (fr)
EP (6) EP3127542B1 (fr)
JP (9) JP2013518107A (fr)
KR (4) KR101964923B1 (fr)
CN (2) CN105311033B (fr)
AP (1) AP3551A (fr)
AU (1) AU2011209788C1 (fr)
BR (1) BR112012018670A2 (fr)
CA (4) CA2967453C (fr)
CL (1) CL2012002080A1 (fr)
CO (1) CO6602152A2 (fr)
CR (1) CR20120423A (fr)
CY (6) CY1116509T1 (fr)
DK (4) DK2932970T3 (fr)
DO (2) DOP2012000205A (fr)
EA (4) EA037601B1 (fr)
EC (1) ECSP12012106A (fr)
ES (4) ES2969969T3 (fr)
FI (2) FI3494972T3 (fr)
FR (2) FR18C1043I2 (fr)
HK (1) HK1250335A1 (fr)
HR (4) HRP20150770T1 (fr)
HU (6) HUE065569T2 (fr)
IL (5) IL221007A (fr)
LT (5) LT3127542T (fr)
LU (1) LUC00090I2 (fr)
MA (1) MA34002B1 (fr)
ME (2) ME02182B (fr)
MX (4) MX367937B (fr)
MY (3) MY188334A (fr)
NO (2) NO2932970T3 (fr)
NZ (4) NZ601319A (fr)
PE (2) PE20160180A1 (fr)
PH (3) PH12012501537A1 (fr)
PL (4) PL3127542T3 (fr)
PT (4) PT2932970T (fr)
RS (4) RS65183B1 (fr)
SG (3) SG10201707183TA (fr)
SI (4) SI3127542T1 (fr)
SM (4) SMT201800290T1 (fr)
TN (1) TN2012000376A1 (fr)
TR (1) TR201807704T4 (fr)
UA (1) UA105556C2 (fr)
WO (1) WO2011094150A1 (fr)
ZA (1) ZA201205586B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT201800290T1 (it) 2010-01-27 2018-07-17 Viiv Healthcare Co Terapia antivirale
NZ706223A (en) 2012-10-23 2018-11-30 Cipla Ltd Pharmaceutical antiretroviral composition
PE20151499A1 (es) 2012-12-21 2015-10-29 Gilead Sciences Inc Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico
EP2767272A1 (fr) * 2013-02-18 2014-08-20 Ratiopharm GmbH Forme posologique pharmaceutique solide de dolutegravir
CA2897137A1 (fr) * 2013-02-18 2014-08-21 Ratiopharm Gmbh Forme galenique pharmaceutique solide de dolutegravir
EP3252058B1 (fr) 2013-07-12 2021-01-20 Gilead Sciences, Inc. Composés polycycliques-carbamoylpyridone et leur utilisation pour le traitement des infections par vih
NO2865735T3 (fr) 2013-07-12 2018-07-21
AU2014324829B2 (en) 2013-09-27 2017-09-07 Merck Sharp & Dohme Corp. Substituted Quinolizine Derivatives useful as HIV integrase inhibitors
IN2014MU00916A (fr) 2014-03-20 2015-09-25 Cipla Ltd
EP3151920B1 (fr) 2014-06-04 2025-08-06 Sanford-Burnham Medical Research Institute Utilisation d'un inhibiteur des antagonistes de la protéine d'apoptose (iap) dans une thérapie contre le vih
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
NO2717902T3 (fr) 2014-06-20 2018-06-23
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
JP6603306B2 (ja) 2014-07-29 2019-11-06 レツク・フアーマシユーテイカルズ・デー・デー ドルテグラビルナトリウムの新規な水和物
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
KR20190057158A (ko) 2015-04-02 2019-05-27 길리애드 사이언시즈, 인코포레이티드 폴리시클릭-카르바모일피리돈 화합물 및 그의 제약 용도
EP3334419A1 (fr) * 2015-08-14 2018-06-20 Sandoz AG Composition pharmaceutique solide d'abacavir, de lamivudine et d'éfavirenz
WO2017205585A1 (fr) * 2016-05-27 2017-11-30 Viiv Healthcare Company Combinaisons, utilisations et traitements correspondants
WO2018028841A1 (fr) * 2016-08-12 2018-02-15 Sandoz Ag Composé pharmaceutique solide d'abacavir, de lamivudine et d'éfavirenz.
WO2018042332A1 (fr) * 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinaisons, utilisations et traitements correspondants
US20200138845A1 (en) * 2017-07-18 2020-05-07 Viiv Healthcare Company Combination Drug Therapy
JP7384783B2 (ja) 2017-07-21 2023-11-21 ヴィーブ ヘルスケア カンパニー Ｈｉｖ感染症及びａｉｄｓを治療するためのレジメン
US20200147092A1 (en) * 2017-07-21 2020-05-14 Viiv Healthcare Company Regimens for treating hiv infections and aids
MX2020003377A (es) * 2017-10-13 2020-09-28 Viiv Healthcare Co Formulacion de tableta farmaceutica de dos capas.
TW202544011A (zh) 2019-03-22 2025-11-16 美商基利科學股份有限公司 橋鍵聯三環胺甲醯吡啶酮化合物及其醫藥用途
CN114901363A (zh) * 2020-01-09 2022-08-12 华盛顿大学 长效治疗剂组合物及其方法
JP7453399B2 (ja) 2020-02-24 2024-03-19 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖ感染症を治療するための四環式化合物及びその使用
KR20230079137A (ko) 2020-09-30 2023-06-05 길리애드 사이언시즈, 인코포레이티드 가교된 트리사이클릭 카르바모일피리돈 화합물 및 이의 용도
PL4196479T3 (pl) 2021-01-19 2024-03-18 Gilead Sciences, Inc. Podstawione związki pirydotriazynowe i ich zastosowania
CN114230579A (zh) * 2021-11-12 2022-03-25 南京艾迪医药科技有限公司 多环氨基甲酰基吡啶酮衍生物及其制备方法和药物组合物
AU2023225805A1 (en) * 2022-02-28 2024-10-17 Jericho Sciences, Llc Methods for viral infections
TWI856796B (zh) 2022-04-06 2024-09-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US7119202B1 (en) 1989-02-08 2006-10-10 Glaxo Wellcome Inc. Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
ZA923641B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en) 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9204015D0 (en) 1992-02-25 1992-04-08 Wellcome Found Therapeutic nucleosides
US5663169A (en) 1992-08-07 1997-09-02 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
IL106507A (en) 1992-08-07 1997-11-20 Merck & Co Inc Pharmaceutical compositions containing benzoxazinones and some novel compounds of this type
GB9402161D0 (en) 1994-02-04 1994-03-30 Wellcome Found Chloropyrimidine intermediates
IL113432A (en) 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
UA49803C2 (uk) 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Спосіб лікування ретровірусних інфекцій
MY115461A (en) 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US5849911A (en) 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
AU727983B2 (en) * 1996-06-25 2001-01-04 Glaxo Group Limited Combinations comprising VX478, zidovudine, FTC and/or 3TC for use in the treatment of HIV
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5965729A (en) 1997-02-05 1999-10-12 Merck & Co., Inc. Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
GB9709945D0 (en) 1997-05-17 1997-07-09 Glaxo Group Ltd A novel salt
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
GB9717928D0 (en) 1997-08-22 1997-10-29 Glaxo Group Ltd Process for the enatioselective hydrolysis of n-derivatised lactams
GB9721780D0 (en) 1997-10-14 1997-12-10 Glaxo Group Ltd Process for the synthesis of chloropurine intermediates
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
US6087383A (en) 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
GB9805898D0 (en) 1998-03-20 1998-05-13 Glaxo Group Ltd Process for the sythesis of hiv protease inhibitors
AU3366899A (en) 1998-03-27 1999-10-18 Regents Of The University Of California, The Novel hiv integrase inhibitors and hiv therapy based on drug combinations including integrase inhibitors
UA72207C2 (uk) 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
GB9809213D0 (en) * 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
GB9815567D0 (en) 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
AU784782B2 (en) 2000-01-31 2006-06-15 Cook Biotech, Incorporated Stent valves and uses of same
BRPI0208811B8 (pt) 2001-04-10 2021-05-25 Pfizer derivados de pirazol, seu uso e processo de preparação, bem como composição farmacêutica compreendendo os mesmos
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
US7638522B2 (en) * 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
TW200403061A (en) 2002-06-04 2004-03-01 Glaxo Group Ltd Pharmaceutical compositions
CN1302779C (zh) * 2002-06-27 2007-03-07 美迪维尔公司 含有阿巴卡韦和阿洛夫定的药物制剂及其用途
EA201100293A1 (ru) * 2003-01-14 2011-08-30 Джилид Сайэнс, Инк. Способ (варианты) и фармацевтическая композиция (варианты) для лечения или профилактики симптомов вич-инфекции
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
EP1720856B1 (fr) * 2004-02-11 2013-08-14 GlaxoSmithKline LLC Inhibiteurs de l'integrase du vih
JP4285353B2 (ja) 2004-03-05 2009-06-24 清水建設株式会社 化学物質放散度評価方法
EP1742642B1 (fr) * 2004-04-14 2008-10-15 Gilead Sciences, Inc. Analogues de phosphonate de composes inhibiteurs de l'integrase du vih
EP3287130A1 (fr) 2004-05-21 2018-02-28 Japan Tobacco Inc. Combinaisons comportant un dérivé d'isoquinolone 4 et inhibiteurs de la protease
US7176196B2 (en) 2004-05-28 2007-02-13 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
EP1930011B1 (fr) 2004-08-23 2011-08-17 Teva Pharmaceutical Industries Ltd Forme cristalline de ibandronate de sodium
WO2006024668A1 (fr) 2004-09-02 2006-03-09 Janssen Pharmaceutica N.V. Chlorhydrate de 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethyl-phenyl]amino]-2-pyrimidinyl]amino]benzonitrile
ATE479693T1 (de) 2004-09-17 2010-09-15 Idenix Pharmaceuticals Inc Phosphoindole als hiv-inhibitoren
US7250421B2 (en) 2005-01-31 2007-07-31 University Of Georgia Research Foundation, Inc. Diketo acids with nucleobase scaffolds: anti-HIV replication inhibitors targeted at HIV integrase
US20090093454A1 (en) 2005-03-04 2009-04-09 Kristjan Gudmundsson Chemical Compounds
UA96568C2 (en) * 2005-04-28 2011-11-25 Глаксосмиткляйн Ллк Polycyclic carbamoyl pyridone derivative as hiv-integrase inhibitor
BRPI0610030B8 (pt) * 2005-04-28 2022-01-11 Glaxosmithkline Llc Composto, composição farmacêutica, e, uso de um composto
CA2610029A1 (fr) 2005-06-01 2006-12-07 Bioalliance Pharma Combinaisons synergiques comprenant un compose de styrylquinoleine et d'autres agents therapeutiques contre une infection au vih
UA108605C2 (uk) * 2005-12-30 2015-05-25 Спосіб покращення фармакокінетики інгібіторів інтегрази віл
SG170795A1 (en) 2005-12-30 2011-05-30 Gilead Sciences Inc Methods for improving the pharmacokinetics of hiv integrase inhibitors
JP5754005B2 (ja) * 2006-01-20 2015-07-22 ヤンセン・アールアンドデイ・アイルランド Ｔｃｍ２７８を用いるｈｉｖ−感染症の長期間処置
US20080039428A1 (en) 2006-06-29 2008-02-14 Panacos Pharmaceuticals, Inc. Antiretroviral combination therapy
PT2069303E (pt) 2006-07-21 2016-06-08 Gilead Sciences Inc Inibidores de protease antiviral
NZ575831A (en) 2006-09-29 2011-12-22 Idenix Pharmaceuticals Inc Enantiomerically pure phosphoindoles as hiv inhibitors
PL2487161T5 (pl) 2007-02-23 2024-09-09 Gilead Sciences, Inc. <div>Modulatory właściwości farmakokinetycznych środków terapeutycznych</div><div> </div>
TW200835693A (en) 2007-02-23 2008-09-01 Auspex Pharmaceuticals Inc Preparation and utility of non-nucleoside reverse transcriptase inhibitors
US8354421B2 (en) 2007-06-29 2013-01-15 Korea Research Insitute Of Chemical Technology HIV reverse transcriptase inhibitors
EA200971115A1 (ru) 2007-06-29 2010-04-30 Корея Рисерч Инститьют Оф Кемикал Текнолоджи Новые ингибиторы обратной транскриптазы вич
CA2692331A1 (fr) 2007-07-06 2009-01-15 Gilead Sciences, Inc. Modulateurs des proprietes pharmacocinetiques de substances therapeutiques
HRP20131128T1 (hr) * 2007-07-12 2013-12-20 Janssen R&D Ireland Kristalni oblik (e) 4-[[4-[[4-(2-cijanoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrila
WO2009058923A1 (fr) 2007-10-31 2009-05-07 Smithkline Beecham Corporation Antagonistes de ccr5 en tant qu'agents thérapeutiques
EP2217573A4 (fr) 2007-11-01 2011-08-31 Uab Research Foundation Traitement et prévention d'infections virales
US8108055B2 (en) 2007-12-28 2012-01-31 Larry Wong Method, system and apparatus for controlling an electrical device
JP2011508748A (ja) * 2008-01-03 2011-03-17 バイロケム ファーマ インコーポレイテッド 新規のルパン誘導体
MX2010007374A (es) 2008-01-03 2010-10-05 Virochem Pharma Inc Nuevos derivados de c-21-ceto lupano, preparacion y uso de los mismos.
AU2008346823B2 (en) 2008-01-04 2015-03-12 Gilead Sciences, Inc. Inhibitors of cytochrome P450
JP2011511812A (ja) 2008-02-14 2011-04-14 バイロケム ファーマ インコーポレイテッド 新規１７βルパン誘導体
WO2009148600A2 (fr) * 2008-06-06 2009-12-10 Concert Pharmaceuticals, Inc. Composés à base de lysine deutérée
DK2320908T3 (en) * 2008-07-25 2014-03-10 Viiv Healthcare Co DOLUTEGRAVIR prodrugs
JP5572168B2 (ja) 2008-12-11 2014-08-13 ビーブ・ヘルスケア・カンパニー カルバモイルピリドンｈｉｖインテグラーゼ阻害剤の製造方法および中間体
JP5086478B2 (ja) 2008-12-11 2012-11-28 塩野義製薬株式会社 カルバモイルピリドンｈｉｖインテグラーゼ阻害剤及びそれらの中間体の合成
SMT201800290T1 (it) 2010-01-27 2018-07-17 Viiv Healthcare Co Terapia antivirale
GB201006038D0 (en) 2010-04-12 2010-05-26 Unilever Plc Improvements relating to antiviral compositions
CN103402516B (zh) 2010-06-17 2018-01-30 富津世生物技术有限公司 用作抗病毒药物的化合物、组合物及使用方法
AU2012236332A1 (en) 2011-04-01 2013-10-31 Chiesi Farmaceutici S.P.A. Short -acting dihydropyridines (clevidipine) for use in reducing stroke damage

Also Published As

Publication number Publication date
HRP20180855T1 (hr) 2018-06-29
FR24C1024I2 (fr) 2025-06-27
PE20121524A1 (es) 2012-12-03
HRP20181531T1 (hr) 2018-11-16
RS65183B1 (sr) 2024-03-29
SI2531027T1 (sl) 2015-08-31
DK2932970T3 (en) 2018-05-28
IL281959A (en) 2021-05-31
PL2932970T3 (pl) 2018-08-31
CY1116509T1 (el) 2017-03-15
HK1250335A1 (en) 2018-12-14
MY202778A (en) 2024-05-21
IL267658A (en) 2019-08-29
EP2531027B1 (fr) 2015-05-06
KR101964923B1 (ko) 2019-04-02
LTPA2018013I1 (lt) 2018-11-12
SMT201800594T1 (it) 2019-01-11
ME02182B (me) 2015-10-20
HUE037812T2 (hu) 2018-09-28
CY2018029I2 (el) 2019-07-10
HRP20240168T1 (hr) 2024-04-26
IL221007A (en) 2016-06-30
ECSP12012106A (es) 2013-05-31
KR20160111536A (ko) 2016-09-26
CO6602152A2 (es) 2013-01-18
US20170216284A1 (en) 2017-08-03
EP2531027A4 (fr) 2013-07-03
US20170079982A1 (en) 2017-03-23
SMT201500177B (it) 2015-09-07
EP2932970B1 (fr) 2018-03-21
PL3127542T3 (pl) 2019-03-29
JP2016145204A (ja) 2016-08-12
CY2024017I2 (el) 2025-05-09
WO2011094150A1 (fr) 2011-08-04
CA3003988C (fr) 2020-01-07
MX356891B (es) 2018-06-19
KR20120128640A (ko) 2012-11-27
PH12012501537A1 (en) 2018-02-07
LTC2932970I2 (lt) 2022-04-25
EP3127542B1 (fr) 2018-08-22
EP2932970A1 (fr) 2015-10-21
SG10201509476RA (en) 2015-12-30
LTC3494972I2 (fr) 2025-11-10
ME03058B (fr) 2019-01-20
SI3127542T1 (sl) 2018-11-30
JP2013518107A (ja) 2013-05-20
CA3060290A1 (fr) 2011-08-04
DK2531027T3 (en) 2015-07-20
NZ627827A (en) 2016-02-26
LTPA2024516I1 (fr) 2024-06-25
PH12018502489A1 (en) 2020-06-15
PH12016500195A1 (en) 2016-12-05
EA025176B1 (ru) 2016-11-30
SMT202400063T1 (it) 2024-03-13
TN2012000376A1 (en) 2014-01-30
HUE040554T2 (hu) 2019-03-28
EP3494972A1 (fr) 2019-06-12
DOP2012000205A (es) 2012-10-15
NZ627824A (en) 2016-02-26
EP4316599A2 (fr) 2024-02-07
PT3494972T (pt) 2024-02-12
NO2018036I1 (no) 2018-10-15
EA037601B1 (ru) 2021-04-20
US20210401850A1 (en) 2021-12-30
PT3127542T (pt) 2018-11-26
JP2021091705A (ja) 2021-06-17
US20180098992A1 (en) 2018-04-12
JP2022071126A (ja) 2022-05-13
MY188334A (en) 2021-11-30
FIC20240016I1 (fi) 2024-05-31
ES2543066T3 (es) 2015-08-14
HK1179522A1 (en) 2013-10-04
EA202190473A3 (ru) 2021-12-31
JP6268386B2 (ja) 2018-01-31
US20200230147A1 (en) 2020-07-23
RS57323B1 (sr) 2018-08-31
SG182614A1 (en) 2012-08-30
CA3003988A1 (fr) 2011-08-04
CY1120457T1 (el) 2019-07-10
BR112012018670A2 (pt) 2018-02-06
CA2967453A1 (fr) 2011-08-04
JP7724619B2 (ja) 2025-08-18
SI3494972T1 (sl) 2024-03-29
ES2670811T3 (es) 2018-06-01
EA201290583A1 (ru) 2013-04-30
EA201892277A1 (ru) 2019-03-29
CN102791129B (zh) 2015-09-30
AU2011209788A1 (en) 2012-08-16
KR101883750B1 (ko) 2018-07-31
CN105311033A (zh) 2016-02-10
PH12016500195B1 (en) 2021-08-04
EA202190473A2 (ru) 2021-06-30
CY2024017I1 (el) 2025-05-09
MX367937B (es) 2019-09-12
IL281959B (en) 2021-12-01
AP2012006445A0 (en) 2012-08-31
CN102791129A (zh) 2012-11-21
AP3551A (en) 2016-01-18
US20160199379A1 (en) 2016-07-14
CN105311033B (zh) 2019-05-07
LT2932970T (lt) 2018-06-25
JP2023085431A (ja) 2023-06-20
HUS2400017I1 (hu) 2024-06-28
UA105556C2 (uk) 2014-05-26
US20160339033A1 (en) 2016-11-24
AU2011209788C1 (en) 2014-08-28
DK3494972T3 (da) 2024-01-29
JP2018127473A (ja) 2018-08-16
DOP2021000147A (es) 2022-01-16
SI2932970T1 (en) 2018-07-31
FR24C1024I1 (fr) 2024-07-26
IL257267B (en) 2019-08-29
LT3127542T (lt) 2018-11-26
KR20170078868A (ko) 2017-07-07
LUC00090I2 (fr) 2019-01-08
CA2787691A1 (fr) 2011-08-04
PL2531027T3 (pl) 2016-01-29
HRP20150770T1 (hr) 2015-08-28
LT3494972T (lt) 2024-03-12
NZ627826A (en) 2016-01-29
HUE065569T2 (hu) 2024-06-28
IL221007A0 (en) 2012-09-24
FR18C1043I1 (fr) 2018-11-30
HUE026849T2 (en) 2016-08-29
US20170119777A1 (en) 2017-05-04
EA032868B1 (ru) 2019-07-31
PT2932970T (pt) 2018-06-08
US20120295898A1 (en) 2012-11-22
AU2011209788B2 (en) 2014-02-06
EP3494972B1 (fr) 2023-12-13
US20250017939A1 (en) 2025-01-16
IL245182A0 (en) 2016-06-30
EP2531027A1 (fr) 2012-12-12
US20180200254A1 (en) 2018-07-19
EA201690872A3 (ru) 2016-12-30
EP4316599A3 (fr) 2024-04-10
FI3494972T3 (fi) 2024-03-01
NZ601319A (en) 2014-08-29
CL2012002080A1 (es) 2012-11-30
CA3060290C (fr) 2022-07-12
EP3351249A1 (fr) 2018-07-25
JP2017008087A (ja) 2017-01-12
JP2019167371A (ja) 2019-10-03
ES2969969T3 (es) 2024-05-23
SG10201707183TA (en) 2017-10-30
CA2967453C (fr) 2018-07-17
CY1121040T1 (el) 2019-12-11
PL3494972T3 (pl) 2024-05-27
DK3127542T3 (en) 2018-11-12
IL245182B (en) 2018-04-30
CA2787691C (fr) 2018-07-17
MX367938B (es) 2019-09-12
CY2018029I1 (el) 2019-07-10
TR201807704T4 (tr) 2018-06-21
US11234985B2 (en) 2022-02-01
CR20120423A (es) 2012-11-22
IL267658B (en) 2021-04-29
PT2531027E (pt) 2015-09-16
HUS1800042I1 (hu) 2018-11-28
US20150238496A1 (en) 2015-08-27
RS54123B1 (sr) 2015-12-31
FR18C1043I2 (fr) 2019-10-11
IL257267A (en) 2018-03-29
EA201690872A2 (ru) 2016-08-31
PE20160180A1 (es) 2016-05-04
ZA201205586B (en) 2014-01-29
RS57728B1 (sr) 2018-12-31
KR101830715B1 (ko) 2018-04-04
HK1209629A1 (en) 2016-04-08
US20170281636A1 (en) 2017-10-05
CY1126771T1 (el) 2025-05-09
EP3127542A1 (fr) 2017-02-08
SMT201800290T1 (it) 2018-07-17
ES2688925T3 (es) 2018-11-07
MY207233A (en) 2025-02-07
US10426780B2 (en) 2019-10-01
NO2932970T3 (fr) 2018-08-18
MX2012008774A (es) 2012-08-17
JP2025131664A (ja) 2025-09-09
KR20180078358A (ko) 2018-07-09

Similar Documents

Publication Publication Date Title
MA34002B1 (fr) Thérapie antivirale
MA44674A (fr) Inhibiteurs de bromodomaine
MA34170B1 (fr) Inhibiteurs de transcriptase inverse non nucléosidiques
MA42410B1 (fr) Oxystérols et leurs méthodes d&#39;utilisation
MA39721A (fr) Nouvelles héteroaryldihydropyrimidines condensées en position 6 pour le traitement et la prophylaxie d&#39;une infection à virus de l&#39;hépatite b
MA31036B1 (fr) Inhibiteurs non nucleosidiques de la transcriptase inverse
MA38182A1 (fr) Compositions pharmaceutiques a action prolongée pur une utilisation dans le traitement ou la prévention d&#39;infections par le virus de l’immunodéficience humaine (vih)
MY186986A (en) Compositions and methods of use of phorbol esters
BRPI0509140A (pt) processos para o tratamento de infecção por hiv
MA38349A1 (fr) Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3)
EP2555798A4 (fr) Procédés et compositions pour l&#39;inhibition de la transmission du vih
WO2018033941A3 (fr) Compositions pharmaceutiques à base d&#39;ibrutinib
WO2015126930A3 (fr) Pharmacothérapie à effet &#34;booster&#34; pour lutter contre les infections à mycobacterium
MA39447B1 (fr) Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
MA31902B1 (fr) Oxazolidinones pour le traitement et/ou la prophylaxie de l&#39;insuffisance cardiaque
TW200738700A (en) HIV integrase inhibitors
MA39448A1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
MA40844A (fr) Compositions pharmaceutiques à action prolongée pour l&#39;hépatite c
MA39533B1 (fr) Composés, composition pharmaceutique et leur utilisation dans le traitement de maladies neurodégénératives
MA46625B1 (fr) Inhibiteurs de lsd1 et leurs utilisations médicales